Skip to main content

The REPROCELL Blog

Research • Reports • Resources

Latest Posts

Featured Posts

Why mRNA Reprogramming Is the Key to Safer and Faster iPSC Generation?

Why mRNA Reprogramming Is the Key to Safer and Faster iPSC Generation?

Discover how mRNA reprogramming enhances the safety, efficiency, and scalability of iPSC generation for therapeutic applications. Explore REPROCELL's innovative technologies and services.

How human fresh tissue models are helping RCD405 achieve regulatory approval

How human fresh tissue models are helping RCD405 achieve regulatory approval

Discover how Arcede Pharma recently used human tissue testing to generate preclinical efficacy data for their compound RCD405.

How to isolate PBMCs from whole blood using density gradient centrifugation

How to isolate PBMCs from whole blood using density gradient centrifugation

Find out how to isolate PBMCs from whole blood samples using density gradient centrifugation a.k.a. the Ficoll Overlay method.

Streamlining PBMC Processing for Reliable Results in Multi-Site Clinical Trials: Key Challenges and Solutions

Streamlining PBMC Processing for Reliable Results in Multi-Site Clinical Trials: Key Challenges and Solutions

Explore the challenges and solutions in PBMC processing for multi-site clinical trials, ensuring reliable results and data integrity for research success.

AI-Designed CRISPR Enables Hypoimmune iPSC Engineering for Off-the-Shelf Cell Therapy

AI-Designed CRISPR Enables Hypoimmune iPSC Engineering for Off-the-Shelf Cell Therapy

REPROCELL's StemEdit platform enables the creation of hypoimmune iPSCs for scalable off-the-shelf cell therapies, reducing immune rejection and enhancing patient access.

REPROCELL Advances iPSC Innovation with MSCRF Support

REPROCELL Advances iPSC Innovation with MSCRF Support

REPROCELL has been awarded the Crystal Award for Innovation by MSCRF, highlighting its advancements in iPSC technology and contributions to regenerative medicine.

12 October 2026

From StemRNA™ Clinical Seed Clone to GMP-Ready Cell Therapy Programs

From StemRNA™ Clinical Seed Clone to GMP-Ready Cell Therapy Programs

Discover how REPROCELL’s StemRNA™ Clinical iPSC Seed Clones streamline the path to GMP-ready cell therapy, simplifying regulatory processes and enabling scalable, high-quality manufacturing.

27 February 2026

Key Challenges in Clinical iPSC Applications: How REPROCELL Helps You Succeed

Key Challenges in Clinical iPSC Applications: How REPROCELL Helps You Succeed

Overcome key challenges in clinical iPSC applications with REPROCELL's ethical sourcing, advanced reprogramming, and tailored solutions for reliable, scalable therapies.

12 May 2025

Prince George’s County Economic Development Corporation Visits REPROCELL USA

Prince George’s County Economic Development Corporation Visits REPROCELL USA

REPROCELL USA hosts Prince George's County Economic Development Corporation, showcasing their biotech services and highlighting the benefits of operating in PG County.

03 March 2025

The Therapeutic Advantage of Induced Pluripotent Stem Cells-Derived Mesenchymal Stem Cells (iMSCs)

The Therapeutic Advantage of Induced Pluripotent Stem Cells-Derived Mesenchymal Stem Cells (iMSCs)

Discover the clinical benefits and advancements of using induced pluripotent stem cells-derived mesenchymal stem cells (iMSCs) in regenerative medicine and therapeutic applications.

24 February 2025

Subjects we write about

  1. 3D Cell Culture
  2. Cell Culture
  3. Central Lab Services
  4. Clinical Capabilities
  5. Disease Modeling
  6. Drug Discovery
  7. Gene Editing
  8. Genomic Services
  9. GMP
  10. Human Tissue Samples
  11. Human Tissue Testing
  12. IBD
  13. Life Sciences
  14. Master Cell Banks
  15. Neurons
  16. Oligonucleotide Synthesis
  17. Pharmacology-AI
  18. Precision Medicine
  19. Product Catalog
  20. Regenerative Medicine
  21. Respiratory Disease
  22. Safety Pharmacology
  23. Skin Disease
  24. Stem Cells